Google
NUVB — NUVATION BIO INC (Healthcare >> Biotechnology)
NUVB FAQ
What is NUVB's P/E ratio?
NUVATION BIO INC (NUVB) currently trades at a P/E ratio of 318.07.
What is NUVB's ROE?
NUVATION BIO INC reports a Return on Equity (ROE) of -45.69%.
What is NUVB's dividend yield?
NUVATION BIO INC offers a dividend yield of 0.00%.
What is NUVB's Deepscope Quality Score?
Deepscope rates NUVB's overall financial quality at 54 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy NUVB?
Deepscope's AI Timing Score for NUVB is 51 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does NUVB belong to?
NUVATION BIO INC is classified under the Healthcare >> Biotechnology sector on the NYSE exchange.
|
USD 4.58
Price
-0.35
(-7.10%)
Day Change
|
|
|---|
NUVB, the overall quality is not quite good ( Quality = 54) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/E ratio is relatively high
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 82 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 4.58 |
| PBV / Sector |
5.37 / 4.79
|
| Earning Per Share | -0.39 |
| PE / Sector |
318.07 / 17.89
|
| PEG or PE/Growth / Sector |
2.32 / 0.56
|
| Average 1M Daily Value |
21.02 M
GREAT
|
| Average 1W Daily Value |
28.49 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
52% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-11 09:55:19 |
| Symbol | NUVB |
| Name | NUVATION BIO INC |
| Sector | Healthcare >> Biotechnology |
| Market | NYSE |
| Listed Shares | 347.20 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,716.64 / 8,963.32 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1500 Broadway, New York, NY, United States, 10036
Phone: 332 208 6102
Website: https://www.nuvationbio.com
Employees: 307
Sector: Healthcare >> Biotechnology
Description: Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
